Amir Nashat
InvestorEntrepreneur Partner at Polaris Partners
Cambridge, Massachusetts
Writes $300K – $2M checks · typically $500K
FoundedAgbiomeaTYR PHARMACamp4 Therapeutics CorpDewpoint TherapeuticsFate TherapeuticsMetacrine
About
Amir Nashat is an entrepreneur partner in Polaris Partners' Boston office who joined the firm in 2002 and serves as a managing partner of Polaris Funds VI–IX. He focuses on portfolio company executive roles and investing in healthcare companies, and is currently CEO of Souffle Therapeutics. He earned an ScD in Chemical Engineering with a minor in Biology at MIT as a Hertz Fellow under Robert Langer, and holds MS and BS degrees in Materials Science and Mechanical Engineering from UC Berkeley.
Amir Nashat @vcamir
Congratulations to the ByHeart team for launching their product: ByHeart No-Compromise Nutrition Infant Formula https://t.co/GMqgCcFwM6
Mar 23, 2022 · ♥ 3 · ⇄ 1
Amir Nashat @vcamir
Wonderful accomplishment by a wonderful team! @Angiejyou , Darcy Mootz, Volker Schellenberger and so many others put their heart and soul into this company. Thanks to Rich Heyman and Jamie Topper for leading the board and syndicate! https://t.co/UtRHAnUlGc
Dec 21, 2021 · ♥ 5
Amir Nashat @vcamir
Interesting ideas coming together in Portland! Wonderful effort, Lars! https://t.co/po2zaR8Tc1
May 20, 2021 · ♥ 1
Invests in
BiotechHealthtech
Experience
- Soufflé TherapeuticsChief Executive Officercurrent2021 — present
- CAMP4 TherapeuticsBoard Membercurrent2016 — presentCambridge, Massachusetts, United States
- Dewpoint TherapeuticsBoard Membercurrent2018 — presentBoston, Massachusetts, United States
- Dewpoint TherapeuticsChief Executive Officer2018 — 2020
- Institute for Protein InnovationBoard Membercurrent2017 — present
- Polaris Venture PartnersEntrepreneur Partnercurrent2021 — present
- Polaris Venture PartnersManaging General Partner2002 — 2021
- Polaris Venture PartnersManaging Partner2002 — 2021Boston, Massachusetts, United States
- AgBiomeBoard Member2012 — 2024
- Morphic TherapeuticBoard Member2017 — 2024
- Scholar RockBoard Member2012 — 2024Cambridge, Massachusetts
- Metacrine, Inc.Board Member2014 — 2023La Jolla, California
- Paratus SciencesChief Executive Officer2020 — 2022New York City Metropolitan Area
- Syros PharmaceuticalsBoard Member2014 — 2022Cambridge, Massachusetts
- FreenomeBoard Member2019 — 2021
- Fate Therapeutics IncBoard Member2008 — 2020
- Jnana TherapeuticsCEO2017 — 2018
- Promedior, Inc.Board Member2008 — 2018Greater Boston Area
- Receptos, Inc.Board Member2012 — 2014
- AVILA THERAPEUTICS, INC.Board Member2007 — 2012
Education
- Massachusetts Institute of TechnologyPhD, Chemical Engineering1996 — 2002
- University of California, BerkeleyMSc, Materials Science Engineering1994 — 1996
- University of California, BerkeleyBSc, Mechanical Engineering1990 — 1994
Same school
Also attended Massachusetts Institute of Technology977
+ 971 more
Also attended University of California, Berkeley987
+ 981 more
Shared employers
Also worked at CAMP4 Therapeutics3
Also worked at Institute for Protein Innovation1
Also worked at Polaris Venture Partners31
+ 25 more
Also worked at Morphic Therapeutic3
Deals · 15
Morphic Holding, Inc.Board seat
via Polaris Partners · filed Mar 2023 · $100M raise
Camp4 Therapeutics CorpBoard seat
via Polaris Partners · filed Jun 2022
AgbiomeBoard seat
via Polaris Partners · filed Feb 2022 · $117.2M raise
Dewpoint TherapeuticsBoard seat
via Polaris Partners · filed Feb 2022 · $150M raise
Syros Pharmaceuticals, Inc.Board seat
via Polaris Partners · filed Dec 2020 · $121.6M raise
Primmune TherapeuticsBoard seat
via Polaris Partners · filed Nov 2020 · $24M raise
Freenome HoldingsBoard seat
via Polaris Partners · filed Aug 2020 · $270M raise
Cartesian Therapeutics (NASDAQ: RNAC)Board seat
via Polaris Partners · filed Jan 2020 · $70M raise
Scholar Rock Holding Corp, Inc.Board seat
via Polaris Partners · filed Jan 2018 · $47M raise
Sofregen MedicalBoard seat
via Polaris Partners · filed Sep 2017 · $9.7M raise
MetacrineBoard seat
via Polaris Partners · filed Nov 2016 · $37.8M raise
Fate TherapeuticsBoard seat
via Polaris Partners · filed Aug 2016 · $10.3M raise
1366 TechnologiesBoard seat
via Polaris Partners · filed May 2016 · $30M raise
Scholar RockBoard seat
via Polaris Partners · filed Jan 2016 · $40M raise
aTYR PHARMABoard seat
via Polaris Partners · filed Apr 2015 · $76.3M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Polaris Partners
Network5
Investors connected to Amir in public investor directories — a warm-intro map.






.jpeg)























